Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

RIBAVIRIN CRS (150 MG)

RIBAVIRIN CRS (150 MG)

36791-04-5

DISCOVER
MITOMYCIN CRS (70 MG)

MITOMYCIN CRS (70 MG)

50-07-7

DISCOVER
TIAMULIN - REFERENCE SPECTRUM(N/A)

TIAMULIN - REFERENCE SPECTRUM(N/A)

NA

DISCOVER
SPIRAPRIL HYDROCHLORIDE MONOHYDRATE CRS (60 MG)

SPIRAPRIL HYDROCHLORIDE MONOHYDRATE CRS (60 MG)

94841-17-5

DISCOVER
FAMOTIDINE FOR SYSTEM SUITABILITY CRS (15 MG)

FAMOTIDINE FOR SYSTEM SUITABILITY CRS (15 MG)

76824-35-6

DISCOVER
ALL-RAC-ALPHA-TOCOPHEROL FOR PEAK IDENTIFICATION CRS (50 MG)

ALL-RAC-ALPHA-TOCOPHEROL FOR PEAK IDENTIFICATION CRS (50 MG)

59-02-9

DISCOVER
ALL-RAC-ALPHA-TOCOPHERYL ACETATE FOR PEAK IDENTIFICATION CRS

ALL-RAC-ALPHA-TOCOPHERYL ACETATE FOR PEAK IDENTIFICATION CRS

7695-91-2

DISCOVER
1,4-SORBITAN CRS (50 MG)

1,4-SORBITAN CRS (50 MG)

27299-12-3

DISCOVER
FOENICULIN FOR PEAK IDENTIFICATION CRS (100 MG)

FOENICULIN FOR PEAK IDENTIFICATION CRS (100 MG)

68952-43-2

DISCOVER
PSEUDOISOEUGENYL 2- METHYLBUTYRATE FOR PEAK IDENTIFICATION C

PSEUDOISOEUGENYL 2- METHYLBUTYRATE FOR PEAK IDENTIFICATION C

8007-70-3

DISCOVER
NEWCASTLE DISEASE VACCINE (INACTIVATED) BRP (40 MG)

NEWCASTLE DISEASE VACCINE (INACTIVATED) BRP (40 MG)

NA

DISCOVER
Hepatitis B vaccine (rDNA) BRP method A (thiomersal free), 0.5mL

Hepatitis B vaccine (rDNA) BRP method A (thiomersal free), 0.5mL

NA

DISCOVER